Urothelial Cancer Patient Derived Organoids (MSK, 2025)

Summary

Urothelial Cancer Patient Derived Organoids (MSK, 2025) is a study catalogued by cBioPortal DataHub under the cancer-type code blca. EvidenceHelix groups it with kidney and bladder studies.

Study description

Targeted sequencing of 90 urothelial cancer tumors, organoids, xenografts, and matched normal samples was performed using MSK-IMPACT as part of the study Determinants of Sensitivity to HER2-targeted Antibody Drug Conjugates in Urothelial Cancers.

Text as published in the source's study metadata.

Citation & PubMed

The source lists no citation or PubMed id for this study.

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

blca_pdx_msk_2025

Short name

not given

Source cancer-type code

blca

Reference genome

not given

Source access groups

not given

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.

Citations

The source lists no citation or PubMed id for this study.

Related studies

• Bladder Cancer (MSK, Eur Urol 2014)

  Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder. Targeted sequencing of 109 tumor samples (MSKCC, European Urology 2014).

  Kidney and bladderMSK studiesSource code blcaPubMed 1

• Bladder Cancer (MSK, J Clin Onco 2013)

  Comprehensive profiling of 97 high-grade bladder tumors, including targeted sequencing of 15 cancer genes

  Kidney and bladderMSK studiesSource code blcaPubMed 1

• Bladder Cancer (MSK, Nat Genet 2016)

  Whole exome and targeted sequencing of 34 plasmacytoid-variant (signet ring cell) tumors of the bladder

  Kidney and bladderMSK studiesSource code blcaPubMed 1

• Bladder Urothelial Carcinoma (DFCI/MSK, Cancer Discov 2014)

  Whole exome sequencing of tumor/normal samples from 50 patients treated with cisplatin-based chemotherapy for muscle invasive urothelial carcinoma.

  Kidney and bladderMSK studiesSource code blcaPubMed 1

• Bladder Urothelial Carcinoma SWOG S1314 Trial (MSK, JCO Precis Oncol 2024)

  Targeted sequencing of 184 muscle-invasive bladder cancer (MIBC) samples and their matched normals using MSK-IMPACT.

  Kidney and bladderMSK studiesSource code blcaPubMed 1

• Nonmuscle Invasive Bladder Cancer (MSK Eur Urol 2017)

  IMPACT sequencing of 105 High Risk Nonmuscle Invasive Bladder Cancer samples.

  Kidney and bladderMSK studiesSource code blcaPubMed 1

• Bladder Cancer (MSK/TCGA, 2020)

  Whole-exome or targeted sequencing of 476 muscle-invasive bladder tumor/normal pairs via TCGA or MSK-IMPACT sequencing.

  Kidney and bladderTCGA (other releases)Source code blcaPubMed 1

• Bladder Cancer (TCGA, Cell 2017)

  Whole-exome sequencing of 412 muscle-invasive bladder tumors and matched normal samples.

  Kidney and bladderTCGA (other releases)Source code blcaPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.